Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized placebo-controlled study of intravenous IRX-010 in healthy participants
NL-OMON58680Phase 1Completed
- Sponsor
- ImmunoRx Pharma
- Start
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Inflammatory Disorders comparing IRX-010 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2023; status: completed.
02
Drugs
IRX-010
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON58680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58680.